Results from a number of clinical trials studying car­filz­o­mib for the treat­ment of multiple myeloma were presented at the 2012 American Society of Clinical Oncology (ASCO) annual meeting last weekend.

Findings from three Phase 1/2 clinical trials showed that several carfilzomib (Kyprolis) com­bi­na­tions are effective for newly diagnosed multiple myeloma patients. Researchers involved in each of these clinical trials presented the results during oral presentations at the ASCO meeting.

In addi­tion, early results from several clinical trials presented at the meeting con­tinue to show that car­filz­o­mib …

Interim results of an ongoing early-stage clin­i­cal trial indicate that dara­tu­mu­mab is safe as a treat­ment for re­lapsed and refractory multiple myeloma. In addi­tion, dara­tu­mu­mab showed promising activity in the trial par­tic­i­pants.

Dr. Torben Plesner of Vejle Hospital in Denmark presented the pre­lim­i­nary results of the Phase 1/2 study at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) on Monday.

“The efficacy [of dara­tu­mu­mab] looks very promising,” said Dr. Andrzej Jakubowiak, the director of the myeloma pro­gram at the University of Chicago, who was not involved in the …

Today is the last day of this year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago. However, the multiple myeloma-related presentations at the meeting concluded yesterday.

A poster session yesterday afternoon featured research on a wide variety of myeloma-related topics, ranging from new treatments being developed for myeloma, to currently used regimens, to second cancers, to precursor myeloma diseases, and much more.

This article summarizes research from that session related to prognostic factors, precursor myeloma diseases, peripheral neuropathy, osteo­necrosis of the jaw, and second cancers.

A summary …

Today concludes this year’s American Society of Clinical Oncology (ASCO) annual meeting, which began on Friday in Chicago.  However, yesterday was the last day with any multiple myeloma-related sessions.

During yesterday’s poster session, important new research findings were summarized on posters throughout a large conference hall.

The studies were on a wide variety of myeloma-related topics ranging from new treatments being developed for myeloma, to currently used regimens, to secondary cancers, to precursor myeloma diseases, and much more.

This update covers some of the myeloma-related studies presented during the poster session, in …

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through tomorrow. How­ever, to­day is the last day with any myeloma-related sessions.

Several myeloma-related oral pre­sen­ta­tions were given this morn­ing and were summarized in an up­date pub­lished earlier to­day (see re­lated Beacon news).

This afternoon featured a poster session in which im­por­tant new re­search findings were summarized on posters throughout a large conference hall.

The stud­ies pre­sented this afternoon were on a wide variety of myeloma-related topics ranging from new treat­ments …

Today is the fourth day of the American Society of Clinical Oncology (ASCO) 2012 annual meeting, and the meeting con­tinued to be filled with in­ter­est­ing re­­sults from clin­i­cal trials in mul­ti­ple myeloma patients.

The day in­cluded a session of oral pre­sen­ta­tions in the late morn­ing that featured re­­sults from three clin­i­cal trials involving immuno­therapy agents.

The three com­pounds, elotuzumab, siltuximab, and daratumumab, belong to the class of drugs called mono­clonal anti­bodies. They work by identifying pro­teins on the surface of myeloma cells and signal for the im­mune sys­tem to …

Today was the third day of the American Society of Clinical Oncology (ASCO) annual meeting, and the morning was filled with oral presentations about important myeloma-related studies.  Most of the talks were about potential new anti-myeloma drugs.

This update summarizes the presentations about panobinostat (Farydak), obatoclax, Treanda (bendamustine), and MLN9708 (ixazomib), which are all being developed as potential multiple myeloma treat­ments.  In addi­tion, the update includes a recap of a presenta­tion about the safety of long-term bis­phos­pho­nate use.

An